Parmax Pharma Ltd

Parmax Pharma Q2 2025: Revenue Jumps 30% & Swings to Profit 📈

- Revenue from operations: ₹25,308.70K (Q2 2025) vs. ₹19,423.11K (previous quarter)

- Total income: ₹25,378.86K (other income: ₹70.16K)

- Expenses: ₹61,625.20K (materials: ₹26,780.68K, employee benefits: ₹6,504.57K)

- Profit before tax: ₹20,783.66K vs. loss of ₹7,644.98K (previous quarter)

- Net profit: ₹20,783.66K vs. net loss of ₹7,644.98K (previous quarter)

- ₹3.5Cr insurance claim filed for Dec 2023 fire incident (survey pending)

- No depreciation charged on clean room & effluent treatment plants (H1 2025)